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Abstract
Background: Resistance to anti-tuberculosis drugs is a serious public health problem. Multi-drug resistant tuberculosis
(MDR-TB), defined as resistance to at least rifampicin and isoniazid, has been reported in all regions of the world. Current
phenotypic methods of assessing drug susceptibility of M. tuberculosis are slow. Rapid molecular methods to detect
resistance to rifampicin have been developed but they are not affordable in some high prevalence countries such as those
in sub Saharan Africa. A simple multi-well plate assay using mycobacteriophage D29 has been developed to test M.
tuberculosis isolates for resistance to rifampicin. The purpose of this study was to investigate the performance of this
technology in Kampala, Uganda.
Methods: In a blinded study 149 M. tuberculosis isolates were tested for resistance to rifampicin by the phage assay and
results compared to those from routine phenotypic testing in BACTEC 460. Three concentrations of drug were used 2,
4 and 10 μg/ml. Isolates found resistant by either assay were subjected to sequence analysis of a 81 bp fragment of the
rpoB gene to identify mutations predictive of resistance. Four isolates with discrepant phage and BACTEC results were
tested in a second phenotypic assay to determine minimal inhibitory concentrations.
Results: Initial analysis suggested a sensitivity and specificity of 100% and 96.5% respectively for the phage assay used at
4 and 10 μg/ml when compared to the BACTEC 460. However, further analysis revealed 4 false negative results from
the BACTEC 460 and the phage assay proved the more sensitive and specific of the two tests. Of the 39 isolates found
resistant by the phage assay 38 (97.4%) were found to have mutations predictive of resistance in the 81 bp region of the
rpoB gene. When used at 2 μg/ml false resistant results were observed from the phage assay. The cost of reagents for
testing each isolate was estimated to be 1.3US$ when testing a batch of 20 isolates on a single 96 well plate. Results were
obtained in 48 hours.
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Conclusion: The phage assay can be used for screening of isolates for resistance to rifampicin, with high sensitivity and
specificity in Uganda. The test may be useful in poorly resourced laboratories as a rapid screen to differentiate between
rifampicin susceptible and potential MDR-TB cases.
Background
The emergence of drug resistant strains of Mycobacterium
tuberculosis is of growing concern. Multi-drug resistant dis-
ease (MDR-TB), where the strain is resistant to both the
major anti-tuberculosis drugs rifampicin and isoniazid,
has been reported in all regions of the world. Incidences
of MDR exceeding 10% of TB caseloads have been
reported in parts of Central Asia, China, Eastern Europe,
Russia and Africa [1]. The prognosis of patients with
MDR-TB is poor and, unless alternative anti-tuberculosis
drugs are administered, they are likely to remain infec-
tious until death. Treatment of MDR-TB is both expensive
and difficult to administer as it requires prolonged treat-
ment of at least 18 months with 'second line' drugs that
exhibit enhanced toxicity Early detection of MDR-TB is
important not only for the patient, but also to limit trans-
mission and the spread of drug resistant disease. Tradi-
tional phenotypic methods of detecting drug resistant
disease are slow due to the protracted growth rate of M.
tuberculosis, with results often taking weeks to obtain.
Rapid molecular methodologies have been developed
that detect mutations predictive of resistance to
rifampicin. These tests examine the rpoB gene encoding
the β-subunit of bacterial DNA dependent RNA polymer-
ase and they have been demonstrated to have high accu-
racy for detecting resistant strains of M. tuberculosis [2]. In
some settings resistance to rifampicin is highly predictive
of MDR-TB [3] and these rapid tests may be used to inves-
tigate suspected MDR-TB cases or to monitor high risk
patients such as those failing standard treatment regi-
mens. However, the new molecular technologies have not
been implemented in resource limited settings due to
their high cost and the requirement for specialist skills
and equipment. Most high prevalence countries continue
to use slow culture-based methods to investigate sus-
pected MDR-TB cases and new simple, rapid tests are
needed that are affordable in these settings.
We have previously described a 'low-tech' rapid method
for investigating the susceptibility of M. tuberculosis to
rifampicin that uses mycobacteriophage D29 [4]. In this
technology mycobacteriophages are allowed to infect the
bacteria, successful replication and production of progeny
phage being indicative of the presence of viable mycobac-
teria. Rifampicin disrupts phage replication by preventing
synthesis of bacterial mRNA and when critical concentra-
tions of this drug are present progeny phage will only be
observed in those strains resistant to the drug [5]. A micro-
well plate version of this technology has been developed
which allows high-throughput screening of M. tuberculosis
isolates [6]. To assess the performance of this simple test
in a low-income, high prevalence country, the method
was transferred to a TB laboratory in Uganda. The study
was part of a multidisciplinary project aimed at develop-
ing strategies for the management of MDR-TB in the Kam-
pala region. A panel of stored strains was selected to
undergo blinded testing by the phage assay. Results were
compared to those obtained by BACTEC 460 system (Bec-
ton Dickinson, Sparks, Maryland, USA); a broth based
phenotypic method routinely employed in this labora-
tory. Strains identified as resistant to rifampicin by either
assay were investigated for mutations in an 81 bp segment
of the rpoB gene by sequencing [7]. Strains with discordant
susceptibility test results were investigated further by
application of a second phenotypic test to assess minimal
inhibitory concentrations of the drug. To appraise the use-
fulness of the phage assay in this setting we also assessed
the rapidity of the test and cost of the reagents.
Methods
All manipulation of live M. tuberculosis was performed
under biohazard category 3 safety conditions using a
microbiological safety cabinet in accordance with local
regulations. One hundred and forty-nine cultures of M.
tuberculosis isolated from 129 patients were selected for
testing at the Mycobacteriology Laboratory of the Joint
Clinical Research Centre (JCRC) in Kampala, Uganda.
Strains for the study were selected from stored cultures
previously isolated from subjects enrolled into several
IRB-approved studies at the Tuberculosis Research Unit in
Uganda. Prior to testing all isolates were freshly sub-cul-
tured on Middlebrook 7H10 agar or Lowenstein-Jensen
(LJ) medium. M. tuberculosis H37Rv was used as a suscep-
tible control strain and M. tuberculosis TMC 331 as a resist-
ant control strain. All strains were subjected to testing for
susceptibility to rifampicin by the phage assay and a tradi-
tional phenotypic test. Statistical analysis of results was
performed using STATA 9.0 (Texas, USA)
Phage assay
The details of the assay and production of phage D29 have
been described previously [8]. Indicator plates for detec-
tion of progeny phage were prepared by adding 10% v/v
of a stationary phase culture of M. smegmatis mc2155 to
1.5% agar in Luria-Bertani broth (Difco, Becton Dickin-
son, Sparks, USA.). Rifampicin was prepared from a stock
solution of 20 mg/ml in dimethylformamide (Sigma-
Aldrich, Poole, UK). 75 μl of drug at 4, 8 and 20 μg/mlAnnals of Clinical Microbiology and Antimicrobials 2007, 6:1 http://www.ann-clinmicrob.com/content/6/1/1
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were placed to the wells of a sterile 96-well plate (Greiner
Labortechnik, Stonehouse, UK) to give a final working
concentration of 2, 4 and 10 μg/ml. Aliquots containing
no drug were also plated.
Bacterial suspensions of isolates under test were prepared
from growth on solid medium in 2 ml of Luria-Bertani
broth supplemented with 1 mM calcium chloride (assay
broth). Samples were vortexed in the presence of glass
beads to disaggregate clumps and left to stand for at least
5 min to allow aerosols to settle. Aliquots of 75 μl were
placed in each well of the microwell plate containing drug
solutions. The plate was then covered, sealed in a plastic
bag and incubated at 37°C for 24 hours. D29 phage sus-
pension was diluted in the assay broth and an aliquot of
50 μl added to each well, giving a final concentration of
2.5 × 107 phage/ml. The plate was resealed and incubated
at 37°C for 90 min. Aliquots of 100 μl of freshly prepared
solution of 30 mM ferrous ammonium sulphate (Sigma-
Aldrich, Poole, UK) were added to each well and mixed by
pipetting. Aliquots of 10 μl from each well were then spot-
ted onto the surface of the M. smegmatis indicator plate.
After absorption of drops in the agar medium the plates
were sealed in plastic bags and incubated overnight at
37°C. The number of plaque forming units (pfu) was
recorded on the drug-containing assay and compared
with the number of pfu on the drug-free control. An iso-
late was recorded as susceptible when no pfu were
observed from drug containing samples and as resistant
when pfu were observed for the assay corresponding to
each drug concentration. The assay and interpretation of
results was performed blinded, without prior knowledge
of the outcome of other susceptibility tests.
Phenotypic susceptibility testing
Drug susceptibility testing was performed using the
BACTEC 460 system (Becton Dickinson, Sparks, Mary-
land, USA) following the manufacturer's recommenda-
tions [9]. One standard drug concentration (2 μg/ml) was
reconstituted from lyophilized drugs supplied by the
manufacturer. The test inoculates were standardized prior
to the addition of 0.1 ml volumes to the vials containing
drug, and to a no drug control. Samples were incubated at
37°C and daily readings were taken and interpretation
performed after comparing the changes in the growth
indices of the inoculated control with that of the test drug.
Nucleotide sequencing
Strains found resistant by either by the BACTEC or the
Phage assay were investigated for mutations in a region of
the  rpoB gene. Sequencing was performed on in the
Genome Research Centre at the London School of
Hygiene & Tropical Medicine. DNA was extracted from
cells grown on Middlebrook 7H11 agar using the CTAB
(hexadecyl trimethyl ammonium bromide)-NaCl method
described by Van Embden and collaborators [10]. A 255-
bp fragment of the rpoB gene including the 81-bp core
region was amplified by PCR using primers RP4T (5'-GAG
GCG ATC ACA CCG CAG ACG T-3') and RP8T (5'-GAT
GTT GGG CCC CTC AGG GGT T-3') [11] and a two-step
amplification programme (3 min at 95°C followed by 30
cycles of [95°C for 30s; 65°C for 45s and 72°C for 1
min]). PCR products were purified through QIAquick
PCR Purification columns (Qiagen, Crawley, UK).
Sequencing of both forward and reverse strands of the
amplicons was performed using the amplification primers
(RP4T and RP8T) and the BigDye Terminator Cycle
Sequencing kit v.3.1. (Applied Biosystems, Foster City,
CA, USA). The sequences obtained were compared to wild
type M. tuberculosis H37Rv RNA-polymerase beta subunit
(rpoB) gene (partial cds U12205) using DNAStar MegA-
lign programme (DNAStar, Wisconsin, USA).
Minimal inhibitory concentration
Minimal inhibitory concentrations (MIC) were deter-
mined using the assay described by Abate et al [12]. This
assay is based on detection of bacterial growth by a redox
dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) (Sigma-Aldrich, Poole, UK). Serial
two-fold dilutions of rifampicin were prepared in the
wells of a sterile flat bottom 96-well plate (Greiner
Labortechnik, Stonehouse, UK) to achieve concentrations
ranging from 0.4 – 100 μg/ml in 100 μl Middlebrook 7H9
broth supplemented with OADC (Becton Dickinson,
Sparks, USA). The inoculum was prepared from fresh
Lowenstein Jensen cultures in Middlebrook broth and
100  μl of bacterial suspension added to each well. A
growth control well containing no drug was included for
each isolate. After seven days of incubation at 37°C, 10 μl
of the MTT solution (5 mg/ml) was added to each well
and the plate was re-incubated overnight. Aliquots of 50
μl of formazan solubilising buffer [1:1 (v/v) 20% SDS:
50% N,N-dimethylformamide (Sigma, Poole, UK)] were
then added to the wells and the plate re-incubated for
three hours. A change in colour from yellow to violet indi-
cated growth of bacteria and the MIC was interpreted as
the lowest concentration that inhibited bacterial growth.
Results
Susceptibility to rifampicin
Of the 149 isolates tested by BACTEC 114 were found sus-
ceptible and 35 resistant to rifampicin at 2 μg/ml. The
number of isolates found susceptible by the phage assay
varied with the concentration of drug used. (Table 1).
When tested at a drug concentration of 2 μg/ml 91 isolates
were found susceptible and 58 resistant. Twenty three iso-
lates found resistant by the phage assay at this drug con-
centration were found susceptible by BACTEC. However,
when concentration of rifampicin was increased to 4 or 10
μg/ml the number of strains found resistant by the phageAnnals of Clinical Microbiology and Antimicrobials 2007, 6:1 http://www.ann-clinmicrob.com/content/6/1/1
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assay dropped to 39 and, when compared to BACTEC,
four isolates with discordant results were recorded. The 35
isolates found resistant by BACTEC were also found resist-
ant by the phage assay at all drug concentrations tested.
Comparison of the phage assay when used at 4 or 10 μg/
ml with the BACTEC provided an overall agreement for
the two tests of 97.3% (n = 145/149, 95% CI; 93.3–
99.3%). If the results from BACTEC are taken as the "gold
standard" for assessing resistance and susceptibility, the
sensitivity of the phage test was 100% (i.e. 35/35: lower
97.5% one sided CI = 90%) and the specificity of the
phage test was 96.5% (i.e. 110/114: 95% CI 91.3–99.1%).
The statistical significance of the difference between the
two assays can be assessed by comparing the number of
discrepant results. For 4 isolates the phage assay indicated
resistance and the BACTEC indicated susceptibility and
there were no isolates which were susceptible by the
phage test and resistant by BACTEC. This difference (4 vs
0) is not statistically significant. However, further genetic
analysis (see below) suggested that the phage assay might
be the more sensitive of the two. Phage assay results were
available within 48 hours.
Mutation analysis
Sequencing of the rpoB core region was performed on the
39 isolates found resistant by the phage assay at 4 or 10
μg/ml and on 18 of the 19 isolates found resistant to 2 μg/
ml but susceptible at 4 or 10 μg/ml.
All but one of the 39 isolates found resistant at 4 or 10 μg/
ml in the phage assay had a rpoB mutation associated with
RMP resistance (Table 2). A double mutation was found
in two isolates. The isolate with no mutation in the rpoB
core region was found resistant by both BACTEC and
phage. All 18 isolates tested that were resistant to 2 μg/ml
but susceptible to 4 μg/ml by phage displayed a wild type
sequence for the rpoB core region. These 18 isolates were
all susceptible by the BACTEC, suggesting their true sus-
ceptibility to rifampicin. The four isolates with discordant
BACTEC and phage results at 4 or 10 μg/ml each harbored
mutations predictive of resistance to rifampicin, two
(both from the same patient) had Leu511Pro mutations
and the other two had a Asp516Tyr and a Leu533Pro
mutation.
Minimal inhibitory concentration (MIC)
MIC's of the four isolates found resistant by phage at 4 or
10 μg/ml of drug but susceptible by BACTEC were deter-
mined by the colorimetric MTT method. The MIC of each
isolate was found to be greater than 50 μg/ml compared
to 2 μg/ml for the reference susceptible isolate (H37Rv)
and all four isolates were judged to be truly resistant, in
agreement with the phage and sequence data.
Discussion
Several methods based on phage D29 replication have
been reported for rapid drug resistance detection in M.
tuberculosis isolates [4,6,13-17]. They differ with respect to
the assay format, drug concentration and criteria for clas-
sifying isolates as resistant or susceptible. The reported
studies indicate that phage replication technology offers
the potential of a rapid, sensitive and specific test for
detecting resistance to rifampicin. The methods reported
initially required three to four days to complete and each
isolate was tested in a single tube format, which is not
convenient for screening large number of isolates. The
phage method we have tested is a simple, low cost assay
taking 48 hours to complete. For our study, the test was
transferred to the Joint Clinical Research Centre (JCRC) in
Kampala, Uganda, to assess its applicability and perform-
ance in a developing country setting.
When used with rifampicin concentrations at 4 or 10 μg/
ml the phage assay was able to correctly detect all isolates
classified as resistant to rifampicin by the BACTEC 460 (n
= 35). Four additional isolates, found susceptible by
Bactec 460, were identified as resistant by the phage assay.
All 4 isolates were found to harbor mutations in the rpoB
gene predictive of resistance, in addition they were found
to have MIC's of over 50 μg/ml suggesting they were truly
resistant. Thus the BACTEC 460 failed to detect 4/39
(10.2%) of rifampicin resistant isolates identified in the
study. It could be postulated that the BACTEC culture was
a mixed population, consisting of predominantly suscep-
tible organisms but with a low level of (emerging)
rifampicin resistant organisms. Retrospective analysis of
BACTEC data showed that one isolate with a Leu533Pro
mutation appeared to have a low level resistant popula-
tion, yet the growth rate (change in growth indices) was
not indicative of borderline resistance. Results of the other
three isolates were clearly susceptible. It is of concern that
the BACTEC was unable to satisfactorily detect four resist-
ant isolates. These isolates were found resistant to other
first line anti-tuberculosis drugs by BACTEC 460 and such
patterns should prompt careful interpretation of the
rifampicin result and/or additional testing.
Initial comparison between the phage assay and BACTEC
methods suggested an estimated sensitivity and specificity
for the phage assay of 100% and 96.5% respectively if the
BACTEC was taken as the "gold standard". However, fur-
ther analysis suggests that the BACTEC may record false
negative results and might not, by itself, be an adequate
method with which to evaluate new tests for drug resist-
ance. In a previous study Albert et al reported a strain
found negative by BACTEC 460 that was positive by a
phage test that was subsequently found to harbor a muta-
tion predictive of resistance [14]. BACTEC 460 has previ-
ously been considered as one of the gold standard tests forAnnals of Clinical Microbiology and Antimicrobials 2007, 6:1 http://www.ann-clinmicrob.com/content/6/1/1
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assessing susceptibility to anti-tuberculosis drugs. How-
ever, proficiency testing of traditional culture based meth-
ods undertaken by the WHO Supranational Laboratory
Network indicates variable accuracy when testing suscep-
tibility to rifampicin with an overall sensitivity and specif-
icity of 97.2% and 96.8% respectively [1].
One isolate that was classified as resistant by both
BACTEC 460 and the phage assay did not have a mutation
in the rpoB core region. It has previously been reported
that mutations in other regions of the gene may be
responsible for resistance in a small proportion of M.
tuberculosis strains [18]. Thus our results suggest the accu-
racy of the phage assay may be higher then that of molec-
ular methods that are limited to screening the 81 bp
genomic region of the rpoB gene.
When the phage assay was used with a drug concentration
of 2 μg/ml 19 susceptible isolates were falsely identified as
resistant. With this drug concentration the phage assay
had a sensitivity of 100% but a specificity of 79.8%. When
used at drug concentration of 4 or 10 μg/ml no false pos-
itives or false positive results were observed and the phage
assay was more accurate than either the BACTEC 460 or
the sequence analysis. Previous studies using mycobacte-
riophage D29 have applied a working concentration of 10
μg/ml [15,16] while a similar study in Spain applied a cut-
off of 5 μg/ml [13]. The results presented here suggest a
drug concentration of 4 μg/ml is adequate for this assay.
For implementation in resource poor settings such as sub-
Saharan Africa new technology should preferably have
low running costs and avoid need for major investment.
The phage assay does not require sophisticated equipment
other than that required for culture of tuberculosis. The
estimated reagent and consumable costs, excluding
labour and overheads, for testing a batch of 20 isolates for
their susceptibility to rifampicin in a single 96 well plate
format was 26 USD i.e. 1.3 USD per isolate.
Conclusion
The phage assay can be used for screening of isolates for
resistance to rifampicin, with high sensitivity and specifi-
city when using a drug concentration of 4 μg/ml. The tech-
nique was easily transferable to a low-income country.
The test is convenient, simple to perform and does not
necessitate quantification of bacilli as required by other
methods. We suggest the test may be useful in poorly
resourced laboratories as a rapid screen to differentiate
between rifampicin susceptible and potential MDR-TB
cases.
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